HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis

References

• Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glaser PE, et al. 2009. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 19: 305–311.
   PubMed Web of Science ®Google Scholar
• Arranz MJ, Rivera M, Munro JC. 2011. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25:933–969.
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. 2011. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res 125:179–186.
   PubMed Web of Science ®Google Scholar
• Basile VS, Masellis M, Potlin SG, Kennedy JL. 2002. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517–2530.
   PubMed Web of Science ®Google Scholar
• Bonhaus DW, Weinhardt KK, Taylor M. 1997. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36:621–629.
   PubMed Web of Science ®Google Scholar
• Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Büttner S, et al. 2012. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry 38: 134–141.
   PubMed Web of Science ®Google Scholar
• Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S, et al. 2013. Genetic association study between antipsychotic- induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J 13:272–279.
   PubMed Web of Science ®Google Scholar
• Clifton PG, Lee MD, Dourish CT. 2000. Similarities in the action of Ro 60-0175, 5-HT2c receptor agonist and D-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berl.) 152: 256–267.
   PubMed Web of Science ®Google Scholar
• De Luca V, Muller DJ, Hwang R, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL. 2007a. HTR2C haplotype and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum Psychopharmacol 22:463–467.
   PubMed Web of Science ®Google Scholar
• De Luca, V, Mueller DJ, de Bartolomeis A, Kennedy JL. 2007b. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 10:697–704.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177–188.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. 2005. The metabolic syndrome. Lancet 365:1415–1428.
   PubMed Web of Science ®Google Scholar
• Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, et al. 2005. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 134B:76–78.
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. 2010. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 55:117–125.
   PubMed Web of Science ®Google Scholar
• Gentile S. 2006. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 29: 303–319.
   PubMed Web of Science ®Google Scholar
• Godlewska B, Olajossy-Hilkesberger L, Ciwoniuk M, Landowski J. 2006. 5-HT2C gene variant influences olanzapine-induced weight gain in men but not in women (Abstract). Am J Med Genet B Neuropsychiatr Genet 141:787.
   Google Scholar
• Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, Olajossy M, Marmurowska-michalowska H, Limon J, Landowski J. 2009. Olanzapine-Induced weight gain is associated with -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 9:234–241.
   PubMed Web of Science ®Google Scholar
• Gregoor JG, Mulder H, Cohen D, van Megen HJ, Egberts TC, Heerdink ER, van der Weide J. 2010. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J Clin Psychopharmacol 30:702–705.
   PubMedGoogle Scholar
• Gregoor JG, van der Weide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER. 2011. Polymorphisms of the LEP-, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics 12: 919–923.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752.
   PubMed Web of Science ®Google Scholar
• Gunes A, Melkersson KI, Scordo MG, Dahl ML. 2009. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 29:65–68.
   PubMed Web of Science ®Google Scholar
• Hayashi A, Suuki M, Sasamata M, Miyata K. 2005. Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats. Psychopharmacology (Berl.) 178:241–249.
   Google Scholar
• Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. 2003. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575–579.
   PubMed Web of Science ®Google Scholar
• Higgins J, Thompson S, Deeks J, Altman D. 2002. Statistical heterogeneity in systematic reviews of clincial trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 7:51–61.
   PubMedGoogle Scholar
• Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, et al. 2012. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 73:1077–1086.
   Google Scholar
• Kane JM. 1988. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 49:12–14.
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. 2010. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 12:345–357.
   PubMedGoogle Scholar
• Kang SH, Lee JI, Chang AK, Joo YH, Kim CY, Kim SY. 2011. Genetic polymorphisms in the HTR2C and peroxisome proliferator- activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. Psychiatry Investig 8:262–268.
   PubMedGoogle Scholar
• Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H. 2008. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 160:308–315.
   PubMed Web of Science ®Google Scholar
• Kuzman MR, Medved V, Bozina N, Grubišin J, Jovanovic N, Sertic J. 2011. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J 11: 35–44.
   PubMedGoogle Scholar
• Laika B, Leucht S, Heres S. Schneider H, Steimer W. 2010. Pharmacogenetics and olanzapine treatment: CYP1A*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 10:20–29.
   PubMed Web of Science ®Google Scholar
• Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH. 2006. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacacol 26:128–134.
   PubMed Web of Science ®Google Scholar
• Lencz T, Malhotra AK. 2009. Pharmacogenetics of antipsychotic- induced side effects. Dialogues Clin Neurosci 11:405–415.
   PubMedGoogle Scholar
• Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. 2012. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17:242–266.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. 2005. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32.
   PubMed Web of Science ®Google Scholar
• Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. 2005. Clozapine-induced weight gain associated with the 5HT2C receptor − 759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 133B:97–100.
   PubMed Web of Science ®Google Scholar
• Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H, Egberts AC. 2007a. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 27:338–343.
   PubMed Web of Science ®Google Scholar
• Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Egberts AC, Scheffer H. 2007b. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J 7:318–324.
   PubMed Web of Science ®Google Scholar
• Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW, et al. 2009. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 29:16–20.
   PubMed Web of Science ®Google Scholar
• Müller DJ, Muglia P, Fortune T, Kennedy JL. 2004. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 49:309–329.
   PubMed Web of Science ®Google Scholar
• Müller DJ, Kennedy JL. 2006. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7: 863–887.
   PubMed Web of Science ®Google Scholar
• Müller DJ, Chowdhury NI, Zai CC. 2013. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry 26:144–150.
   PubMed Web of Science ®Google Scholar
• Nastallah HA. 2008. Atypical antipyschotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27–35.
   Google Scholar
• Navarro-Mateu F, Escámez T, Koenen KC, Alonso J, Sánchez-Meca J. 2013. Meta-analyses of the 5-HTTLPR polymorphism and post-traumatic stress disorder. PLoS One 8:e66227
   Web of Science ®Google Scholar
• Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D. 2004. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 9:55–64.
   PubMedGoogle Scholar
• Opgen-Rhein C, Brandl EJ, Muller DJ, Neuhaus Ah, Tiwari AK, Sander T, Dettling M. 2010. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 11:773–780.
   PubMed Web of Science ®Google Scholar
• Park YM, Cho JH, Kang SG, Choi JE, Lee SH, Kim L, Lee HJ. 2008. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 33:55–60.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Zhang ZJ, Zhang XB. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086–2087.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Hill MJ, Kirk SL. 2006. The 5-HT2C receptor and antipsychotic induced weight gain - mechanisms and genetics. J Psychopharmacol 20:15–18.
   PubMedGoogle Scholar
• Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, et al. 2012. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J 12:62–67.
   PubMed Web of Science ®Google Scholar
• Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK, et al. 2007. 759 C/T polymorphism of the 5-HT2c receptor gene and early phase weight gain associated with antipyschotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 31:673–677.
   PubMed Web of Science ®Google Scholar
• Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. 2012. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther 92:235–242.
   PubMed Web of Science ®Google Scholar
• Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, et al. 2010. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11:1561–1571.
   PubMed Web of Science ®Google Scholar
• Simansky KJ. 1996. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 73:37–42.
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. 2002. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on out come. Ann Clin Psychiatry 14:123–129.
   PubMedGoogle Scholar
• Templeman LA, Reynolds GP, Arranz B, San L. 2005. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15: 195–200.
   PubMedGoogle Scholar
• The IDF consensus worldwide definition of the metabolic syndrome. 2006. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed on January 28, 2014.
   Google Scholar
• Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, et al. 2008a. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 69: 1416–1422.
   PubMed Web of Science ®Google Scholar
• Ujike H, Nomura A, Morita Y, Okahisa Y, Kotaka T, Kodama M, et al. 2008b. Analyses of genetic factors in olanzapine-induced weight gain in schizophrenic patients. Eur Neuropsychopharm 18:S417.
   Google Scholar
• Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT, Kennett GA. 2003. Oral administration of the 5-HT2Creceptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (Berl.) 167:274–280.
   Google Scholar
• Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. 2004. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analysis. Ottawa, Ontario: Ottawa Health Research Institute.
   Google Scholar
• Yevtushenko OO, Cooper SJ, O’Neil R, Doherty JK, Woodside JV, Reynolds GP. 2008. Influence of 5-HT2C receptor and leptin gene polymorphism, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 192: 424–428.
   PubMed Web of Science ®Google Scholar